These intensive research and development efforts are in response to the increasing prevalence of the disease and related co-morbidities, realization by care givers that successful glycemic control will likely require combination therapy, a growing understanding of the pathophysiology of the disease, and the identification and validation of new pharmacological targets
Notably, the 23andMe data did not reveal an association with BMI or weight, indicating that the association of the SNP may be identifiable more strongly in the context of GLP1 treatment
What varies is the incidence, the severity curve, and (in retatrutide's case) the appearance of a new signal
The realistic timeline Based on the current state of the clinical program, regulatory precedent, and publicly available information from Eli Lilly, here is the most realistic projection: Mid to late 2026: Remaining TRIUMPH, TRANSCEND, and SYNERGY Phase 3 results are reported
Outer upper arm: The back or outer portion of the upper arm works, though this site can be harder to reach on your own
With the right care and treatments, you can protect your skin during weight loss and restore some volume and structure afterwards or during
